AN2 Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

AN2 Therapeutics, Inc.'s free cash flow has increased -39.43% from $-49.26M last year to $-29.83M, signaling increasing performance

AN2 Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

AN2 Therapeutics, Inc. has insufficient data to evaluate this check.

AN2 Therapeutics, Inc. has a net cash position, so leverage is healthy.

AN2 Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

AN2 Therapeutics, Inc. has insufficient data to evaluate this check.

AN2 Therapeutics, Inc.'s short-term assets of $59.94M exceed its short-term liabilities of $8.72M

AN2 Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

AN2 Therapeutics, Inc.'s return on equity of -52.35%, is lower than 15.00%, indicating bad performance

AN2 Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

AN2 Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

AN2 Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

AN2 Therapeutics, Inc. has negative free cash flow, indicating cash burn

AN2 Therapeutics, Inc.'s yearly earnings has increased -31.46% since last year from $-51.32M to $-35.17M, signaling increasing performance

AN2 Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -45.31% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

AN2 Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

AN2 Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

AN2 Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

AN2 Therapeutics, Inc. has insufficient data to evaluate this check.

AN2 Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

AN2 Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

AN2 Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

AN2 Therapeutics, Inc. has insufficient data to evaluate this check.

AN2 Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

AN2 Therapeutics, Inc. has a price-to-book ratio of 2.46x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

AN2 Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue